The talk will briefly review challenges and opportunities for evaluating PROs both in clinical trials settings and clinical practice settings. It will then describe the PROTEUS Consortium and it’s available (and planned) resources that are designed to help stakeholders and users improve these applications of PROs in research and patient care.
Dr. Michael Brundage, MD MSC FRCP(C) is a Professor of Oncology and of Public Health Sciences at Queen’s University in Kingston. He graduated from medical school at Queen’s and completed training in Radiation Oncologist at Princess Margaret Hospital and University of Toronto, followed by post-graduate training in Epidemiology at Queen’s, where he is now a Clinician Scientist. His research focuses on patient-reported outcomes and quality of life measurement (both in clinical practice and in clinical trials) and on quality of cancer care, with an emphasis on quality initiatives in oncology.
In the context of his research portfolio he has had the privilege of working with many national and international organizations. These include his roles as the Quality Lead for the Radiation Oncology Program at Cancer Care Ontario and member of the Cancer Quality Council of Ontario, the Canadian Cancer Trials Group, EORTC and ISOQOL. He is the Past-President of the Canadian Association of Radiation Oncology, and a founding member of the Canadian Partnership for Quality of Radiotherapy, an organization that promotes knowledge dissemination and implementation strategies for the use of PROs in clinical practice in Canada. He is co-PI for the PROTEUS Consortium (with the PI Dr. Claire Snyder) which also promotes quality of PROs both in clinical practice and clinical trials internationally.